Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, sending shares higher in pre-market trading. Concurrently, Merck & Co. (MRK) lowered its sales outlook despite topping third quarter estimates,
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Hosted on MSN1d
What's Behind the Insider Buying on This High-Yield Stock?Bristol-Myers Squibb has demonstrated its commitment to shareholders with ... Overall, the mood on Wall Street is tepid ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...
Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and ... Analyst’s Disclosure: I/we have a beneficial ...
Investor's Business Daily on MSN2d
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug FailsBristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback